The Efficacy of Oral Labetalol Versus Oral Methyldopa for the Management of Pregnancy-Induced Hypertension: A Quasi-Experimental Study
Oral Labetalol Versus Oral Methyldopa for the Pregnancy-Induced Hypertension
DOI:
https://doi.org/10.54393/pjhs.v7i9.3775Keywords:
Labetalol, Methyldopa, Pregnancy-Induced Hypertension, Third Trimester, Target Blood Pressure, HypotensionAbstract
Hypertensive disorders of pregnancy are a common complaint faced by obstetricians in routine clinical practice. Careful monitoring of both the mother and fetus is a crucial part of treatment. Numerous anti-hypertensive drugs are available in the market. Objectives: To compare the efficacy and safety of oral labetalol versus oral methyldopa in the management of pregnancy-induced hypertension during the third trimester. Methods: This quasi-experimental comparative study was carried out in the Department of Obstetrics and Gynecology, Avicenna Hospital, Lahore. Hundred females were enrolled and divided into two groups. Half of the females were prescribed labetalol (Group A), and half were prescribed methyldopa (Group B). After 5 days, the efficacy and safety of the drugs were noted. Data were analyzed in SPSS version 26.0. Results: The mean age of females was 28.62 ± 6.91 years in the labetalol group, while 29.86 ± 6.69 years in the methyldopa group. The mean SBP was reduced from 148.50 ± 4.43 mmHg to 122.00 ± 9.26 mmHg with labetalol and from 148.40 ± 4.99 mmHg to 127.50 ± 14.44 mmHg with methyldopa. Likewise, mean DBP was reduced from 98.10 ± 4.62 mmHg to 73.10 ± 12.37 mmHg with labetalol and from 98.20 ± 4.71 mmHg to 78.60 ± 11.56 mmHg with methyldopa. Target BP was achieved in 42 (84%) with labetalol, while in 30 (60%) females with methyldopa (p<0.05). Hypotension was noted in 4 (8%) females in the methyldopa group only (p<0.005). Conclusion: Labetalol has been proven to be more efficient in controlling blood pressure than methyldopa.
References
Mathew R, Devanesan BP, Sreedevi NS. Prevalence of Hypertensive Disorders of Pregnancy, Associated Factors, and Pregnancy Complications in a Primigravida Population. Gynecology and Obstetrics Clinical Medicine. 2023 Jun; 3(2): 119-23. doi: 10.1016/j.gocm.2023.01.002. DOI: https://doi.org/10.1016/j.gocm.2023.01.002
Cífková R. Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview. High Blood Pressure and Cardiovascular Prevention. 2023 Jun; 30(4): 289. doi: 10.1007/s40292-023-00582-5. DOI: https://doi.org/10.1007/s40292-023-00582-5
Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z et al. Epidemiological Trends of Maternal Hypertensive Disorders of Pregnancy at the Global, Regional, and National Levels: A Population‐Based Study. BioMed Central Pregnancy and Childbirth. 2021 May; 21(1): 364. doi: 10.1186/s12884-021-03809-2. DOI: https://doi.org/10.1186/s12884-021-03809-2
Jiang L, Tang K, Magee LA, Von Dadelszen P, Ekeroma A, Li X et al. A Global View of Hypertensive Disorders and Diabetes Mellitus During Pregnancy. Nature Reviews Endocrinology. 2022 Dec; 18(12): 760-75. doi: 10.1038/s41574-022-00734-y. DOI: https://doi.org/10.1038/s41574-022-00734-y
Beech A and Mangos G. Management of Hypertension in Pregnancy. Australian Prescriber. 2021 Oct; 44(5): 148. doi: 10.18773/austprescr.2021.039. DOI: https://doi.org/10.18773/austprescr.2021.039
Khalid H, Parveen F, Ismail A, Detho S, Khalid U. Efficacy of Labetalol versus Methyldopa in Pregnancy-Induced Hypertension among Patients Visiting a Tertiary Care Hospital. Journal of the Society of Obstetricians and Gynecologists of Pakistan. 2021 Jun; 11(2): 131-4.
Bej P and Das S. Effect of Labetalol for Treating Patients with Pregnancy-Induced Hypertension: A Systematic Review. Journal of the Practice of Cardiovascular Sciences. 2022 Sep; 8(3): 144-51. doi: 10.4103/jpcs.jpcs_69_22. DOI: https://doi.org/10.4103/jpcs.jpcs_69_22
Saleem F, Mumtaz S, Aslam S, Hamid I, Sibtain S, Fatima U. Comparison of Mean Arterial Pressure in Oral Labetalol versus Methyldopa in Pregnancy-Induced Hypertension. Journal of the Society of Obstetricians and Gynecologists of Pakistan. 2025 Dec; 15(4): 337-41. doi: 10.71104/jsogp.v15i4.997. DOI: https://doi.org/10.71104/jsogp.v15i4.997
Afroz T, Ferdous R, Rahman MA. The Safety and Efficacy of Labetalol vs. Methyldopa in Treatment of Pregnancy-Induced Hypertension. International Journal of Gynecology and Obstetrics. 2024; 6(1): 38-42. doi: 10.33545/26649004.2024.v6.i1a.28. DOI: https://doi.org/10.33545/26649004.2024.v6.i1a.28
Malik BA, Momina SB, Ashraf T. Comparison Between Methyldopa and Combination of Methyldopa and Nifedipine in Terms of Mean Change in Blood Pressure in Pregnancy-Induced Hypertension. Pakistan Journal of Medical and Health Sciences. 2021; 15(7): 1703-5. doi: 10.53350/pjmhs211571703. DOI: https://doi.org/10.53350/pjmhs211571703
Nahar K, Shikder S, Khanam KA, Quamruzzaman M, Shahnewaj SM, Rahman SM. Efficacy of Labetalol and Methyldopa in the Treatment of Pregnancy-Induced Hypertension. Scholars Journal of Applied Medical Sciences. 2023 Feb; 11(2): 366-71. doi: 10.36347/sjams.2023.v11i02.015. DOI: https://doi.org/10.36347/sjams.2023.v11i02.015
Rauf H, Zubair F, Shaheen S, Laique T. Oral Labetalol versus Oral Methyldopa for the Management of Pregnancy-Induced Hypertension. Age (Years). 2021; 28: 6-11.
Kumari R, Raman RK, Kumari U. Comparison of Therapeutic Effects of Labetalol with Other Anti-Hypertensives in Control of Hypertension in PIH (Pregnancy Induced Hypertension) in a Tertiary Care Hospital. International Journal of Academic Medicine and Pharmacy. 2023; 5(5): 1230-4.
Arshad M, Farooq S, Majeed K, Khalid U, Afsheen A, Artemis P. Labetalol versus Methyldopa for Treatment of Pregnancy-Induced Hypertension. Pakistan Armed Forces Medical Journal. 2024 Aug; 74(4): 1024. DOI: https://doi.org/10.51253/pafmj.v74i5.9860
Khatun A, Parven R, Naznin S, Murshid-Ur-Rahman M. A Comparative Study of Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension. International Journal of Clinical Obstetrics and Gynaecology. 2024; 8(4): Part B. doi: 10.33545/gynae.2024.v8.i4b.1485. DOI: https://doi.org/10.33545/gynae.2024.v8.i4b.1485
Kumar CH, Roy S, Aishwarya T, Setty CS, Afreen O, Maheshwari A et al. Pregnancy-Induced Hypertension: Risk Factors and Current Treatment Strategies. Cellular, Molecular and Biomedical Reports. 2023 Dec; 3(4): 197-204. doi: 10.55705/cmbr.2023.387076.1111. DOI: https://doi.org/10.55705/cmbr.2023.387076.1111
Bhat AD, Keasler PM, Kolluru L, Dombrowski MM, Palanisamy A, Singh PM. Treatment of Acute-Onset Hypertension in Pregnancy: A Network Meta-Analysis of Randomized Controlled Trials Comparing Anti-Hypertensives and Route of Administration. Pregnancy Hypertension. 2023 Dec; 34: 74-82. doi: 10.1016/j.preghy.2023.10.005. DOI: https://doi.org/10.1016/j.preghy.2023.10.005
Ale B, KC H, Sah SK, Gurung S, Barma S, Bhandari SR. Prevalence, Associated Risk Factors, and Pharmacological Management of Pregnancy-Induced Hypertension in Pregnant Women Visiting the Gynecological Department at Tuth. Journal of Medical Research and Clinical Case Reports. 2024; 1.
Ma and Hu P. Meta-Analysis of the Clinical Efficacy of Various Medications for Treating Pregnancy-Induced Hypertension. Pakistan Journal of Pharmaceutical Sciences. 2025 Jul; 38(4). DOI: https://doi.org/10.36721/PJPS.2025.38.4.REG.12626.1
Al Khalaf S, Khashan AS, Chappell LC, O’Reilly ÉJ, McCarthy FP. Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: A Population-Based Study of Linked Electronic Health Records. Hypertension. 2022 Jul; 79(7): 1548-58. doi: 10.1161/HYPERTENSIONAHA.122.18920. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.18920
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
